SVB Securities launched coverage of Moonlake Immunotherapeutics (NASDA:MLTX) with an “outperform” rating and $17 price target. The stock closed at $9.01 on Aug. 24. Moonlake is a clinical-stage biopharmaceutical company...
Ladenburg Thalmann initiated coverage of Kiora Pharmaceuticals (NASDAQ:KPRX) with a “buy” rating and price target of $6.50. The stock closed at 13 cents on Aug. 24. Kiora is focused on bringing treatments to the market...
Maxim Group downgraded Aridis Pharmaceuticals (NASDAQ:ARDS) to “hold” from “buy” and removed its price target, citing capital concerns and key clinical programs. The stock closed at $2.19 on Aug. 15. In a 10-Q report...
Dawson James Securities slashed its price target for Aditxt Therapeutics (NASDAQ:ADTX) to $1 from $6, but maintained a “buy” rating, noting that cash is tight and a capital raise is expected. The stock closed at 17...
Stifel downgraded IDEAYA Biosciences (NASDAQ:IDYA) to “hold” from “buy” and reduced its price target to $13 from $16 “on the belief that it’s difficult to gain high conviction in the MTAP/MAT2A thesis (we ascribe...
Cantor Fitzgerald initiated coverage of Mereo BioPharma (NASDAQ:MREO) with an “overweight” rating and $4 price target. The stock closed at $1.15 on Aug. 11. Mereo is a clinical-stage biopharmaceutical company that is...
BTIG reduced its price target for Pear Therapeutics (NASDAQ:PEAR) to $5 from $11 but maintained its “buy” rating after the company missed second quarter revenue consensus and lowered 2022 revenue guidance. The stock...
Cantor Fitzgerald downgraded TerrAscend (OTCQX:TRSSF) to “neutral” from “overweight” and reduced its price target to $2.85 from $6.45 on lower estimates and sectoral derating. The stock closed at $2.40 on Aug. 11...
SVB Securities downgraded 4D Molecular Therapeutics (NASDAQ:FDMT) to “market perform” from “outperform” and reduced its price target to $12, citing an elevated risk to the lead Fabry disease program, along with an...
BTIG raised its price target for Acutus Medical (NASDAQ:AFIB) to $2.50 from $1.50 after the company beat consensus estimates for second quarter revenue. The stock closed at $1.66 on Aug. 11. Acutus Medical is a cardiac...